Project Grant R01HL174635
- This five-year Project Grant award of $166,395.00, issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) and effective September 1, 2025 through August 31, 2030, supports a research career development plan at Columbia University Medical Center. The award funds an Assistant Professor of Pediatrics in the Division of Pediatric Pulmonology to conduct research on neonatal respiratory progenitor cell function in response to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a Project Grant of $1,035,944 on September 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the BILDING-ACTION (Bangladesh Infant Lung Development-ACS for Improving Outcomes in Preterm Newborns) longitudinal cohort study. The project leverages two rigorous World Health Organization (WHO) randomized controlled trials to assess the efficacy of antenatal...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $156,168 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center under the Cardiovascular Diseases Research program (CFDA 93.837) for a two-year project spanning August 1, 2025, through July 31, 2027. This project grant funds research exploring the role of the Hedgehog pathway-primary cilia axis in human lung alveologenesis and disease, with specific focus on...
- Federal Project Grant Summary Baylor College of Medicine received a $773,868 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2030. This research project investigates the mechanistic and therapeutic roles of regulatory T cells (Tregs) in bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH), the most common infantile chronic lung...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $106,391 to The Regents of the University of Colorado (University of Colorado-Denver) under the Cardiovascular Diseases Research program (CFDA 93.837) on September 9, 2025, with a completion date of August 31, 2027. This research initiative investigates the role of developmental dysanapsis—the disproportionate growth of lung compartments—in bronchopulmonary dysplasia (BPD), the chronic...
- Federal Project Grant Summary Cincinnati Children's Hospital Medical Center received a $721,826 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2025, with an ultimate completion date of March 31, 2029. The award funds basic molecular and translational research investigating MEOX2 as a critical regulator of alveolar fibroblast function and its role in lung development and disease...
- Federal Project Grant Award Summary Boston Medical Center Corporation received $166,752 in Project Grant funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2030. This five-year Career Development Award (K08) supports Dr. Taglauer's research training and career development as an independent clinician-scientist in neonatal lung disease. The award funds the development...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a Project Grant totaling $192,672 (awarded August 1, 2025, with completion scheduled for July 31, 2030) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct an investigation of omics for bronchopulmonary dysplasia (BPD). The research will deliver three primary outputs: (1) identification of distinct lipid and metabolomic profiles...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $179,330 to the Research Institute at Nationwide Children's Hospital effective August 1, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This K23 Mentored Patient-Oriented Research Career Development Award supports Dr. Matthew J. Kielt, Assistant Professor of Pediatrics at Ohio State University College of Medicine and Nationwide Children's Hospital,...
ROLE OF LIVER KINASE B1 IN THE DECREASED ANGIOGENESIS IN BRONCHOPULMONARY DYSPLASIA - PROJECT SUMMARY BRONCHOPULMONARY DYSPLASIA (BPD) IS THE MOST COMMON COMPLICATION OF PREMATURE BIRTH AND INCREASES THE RISK OF MORTALITY, LONG-TERM MEDICAL NEEDS, AND NEURO-DEVELOPMENTAL IMPAIRMENTS. EXPOSURE OF PRETERM LUNG TO SUPPLEMENTAL OXYGEN (HYPEROXIA) INCREASES THE RISK OF BPD, DUE TO ARREST OF ALVEOLAR AND VASCULAR GROWTH. IMPAIRED ANGIOGENESIS IS A KEY COMPONENT OF THIS GROWTH ARREST IN THE LUNG. LUNG ENDOTHELIAL CELLS (LEC) INITIATE ANGIOGENESIS TO ESTABLISH VASCULAR NETWORKS; THE MECHANISMS OF DECREASED ANGIOGENESIS IN HYPEROXIA REMAIN UNKNOWN. OUR RECENT STUDIES IN A NEONATAL MOUSE MODEL OF OXYGEN INDUCED BPD IDENTIFIED DECREASED EXPRESSION OF LIVER KINASE B1 (LKB1) IN THE LUNGS. LKB1 REGULATES THE FUNCTION OF 5'AMP ACTIVATED PROTEIN KINASE (AMPK), A KEY METABOLIC REGULATOR, AND THE EXPRESSION OF SUCROSE NON FERMENTER RELATED KINASE (SNRK), A NOVEL AMPK RELATED KINASE; BOTH WERE DECREASED IN HYPEROXIA EXPOSED LUNGS. LEVELS OF PGC-1A, AN AMPK TARGET REQUIRED FOR MITOCHONDRIAL BIOGENESIS, WERE ALSO DECREASED IN HYPEROXIA EXPOSED LUNGS. TREATMENT OF MOUSE PUPS WITH THE AMPK ACTIVATOR, METFORMIN, RESTORED MITOCHONDRIAL BIOGENESIS AND ANGIOGENESIS IN THE LUNG. THE MECHANISTIC LINK BETWEEN MITOCHONDRIAL DYSFUNCTION AND IMPAIRED ANGIOGENESIS REMAINS UNCLEAR. ENDOTHELIAL CELLS (EC) INITIATE ANGIOGENESIS THROUGH COMMITMENT TO EITHER A MIGRATORY, TIP CELL PHENOTYPE WHICH INITIATES THE SPROUT OR A PROLIFERATIVE STALK CELL PHENOTYPE THAT ELONGATES THE VASCULAR SPROUT. NOTCH LIGANDS DETERMINE THE EC PHENOTYPE WITH THE TIP CELLS EXPRESSING DELTA LIKE 4 (DLL4) AND STALK CELLS, JAGGED1. OUR PRELIMINARY DATA SHOW THAT HYPEROXIA INCREASES DLL4 AND DECREASES JAG1 LEVELS IN LEC. BASED ON OUR PILOT DATA, WE HYPOTHESIZE THAT THE EXPOSURE OF PRETERM LUNGS TO HYPEROXIA DECREASES LKB1-AMPK SIGNALING, WHICH LEADS TO DECREASED MITOCHONDRIAL BIOGENESIS AND SUSTAINED ALTERATIONS IN NOTCH SIGNALING TO IMPAIR ANGIOGENESIS. WE PROPOSE TWO SPECIFIC AIMS TO INVESTIGATE OUR HYPOTHESIS: (1) DETERMINE THE MECHANISM BY WHICH HYPEROXIA DECREASES LKB1-DEPENDENT SIGNALING AND MITOCHONDRIAL BIOGENESIS. EXPERIMENTS UNDER THIS AIM WILL INVESTIGATE THE ROLE OF LKB1 DOWNREGULATION IN DECREASED MITOCHONDRIAL NUMBER AND FUNCTION IN HYPEROXIA, USING GENETIC GAIN AND LOSS OF FUNCTION STUDIES IN LEC AND HUMAN PULMONARY MICROVASCULAR ENDOTHELIAL CELLS AND GENETICALLY ALTERED MICE. (2) INVESTIGATE THE ROLE OF DECREASED LKB1-DEPENDENT SIGNALING IN THE IMPAIRED ANGIOGENESIS IN LUNG DURING HYPEROXIA. EXPERIMENTS UNDER THIS AIM WILL INVESTIGATE THE ROLE OF LKB1-AMPK DOWNREGULATION IN THE DECREASED JAG1/INCREASED DLL4 EXPRESSION AND THE ROLE OF THIS ALTERED PHENOTYPE OF EC IN DECREASED ANGIOGENESIS IN THE LUNG IN HYPEROXIA. AIM 2 STUDIES WILL USE MICE WITH ENDOTHELIAL SPECIFIC LOSS OR GAIN OF LKB1, PGC-1A, AND JAG1. DELINEATION OF THE MECHANISMS OF DECREASED ANGIOGENESIS IN BPD CAN IDENTIFY NOVEL THERAPEUTIC TARGETS TO RESTORE LUNG GROWTH IN BPD. SINCE THE AMPK ACTIVATOR, METFORMIN IS APPROVED FOR CLINICAL USE, OUR STUDIES ARE HIGHLY TRANSLATABLE TO THE PREVENTION OF BPD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $645.5k | 7/23/25 | ||
| Not listed | $645.5k | 7/9/24 |